The FDA-Approved Melanotan

Melanotan 1 stands apart in this library: it is a genuine FDA-approved drug. Developed as afamelanotide and marketed as Scenesse, it is approved in the US and EU for erythropoietic protoporphyria (EPP) — a rare genetic disorder where light exposure causes severe, painful phototoxicity because of accumulated protoporphyrins.

For EPP patients, the increased melanin from afamelanotide provides real photoprotection and dramatically improves quality of life. This is the key distinction members emphasize: the approval is for a serious rare disease, not for cosmetic tanning. And critically, the approved drug is a subcutaneous implant releasing ~16mg over two months — not a reconstituted vial. The thread below discusses why that formulation matters and why cosmetic use of MT-1 is not the same as the approved drug.

This is one of the few peptides where the clinical evidence is strong and the mechanism is well-characterized — but the approved context is narrow.